Every material Form 8-K Acurx Pharmaceuticals, Inc. filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Acurx Pharmaceuticals agreed on April 15, 2026 to sell about $2.5 million of common stock and pre-funded warrants in a registered direct offering at $3.03 per share, before placement agent fees and expenses. A concurrent private placement adds Series H warrants for 1,650,170 shares at $2.78 per share, which could bring up to about $4.6 million if fully exercised, so existing shareholders face dilution and the warrants are not assured to be exercised.
Registered offering: 816,068 common shares at $3.03 per share, plus pre-funded warrants for 9,017 shares at $3.029, for about $2.5 million gross before fees
Concurrent private placement: Series H warrants for 1,650,170 shares at $2.78 per share, exercisable immediately and expiring 24 months after the resale registration becomes effective
Placement agent H.C. Wainwright & Co. receives a cash fee of 6.0% of gross proceeds, plus up to $50,000 for legal fees and $15,950 for clearing expenses
Closing is expected on or about April 16, 2026; the company plans to use proceeds for working capital and general corporate purposes
Acurx Pharmaceuticals said executive officers voluntarily agreed to base salary reductions of 10%, effective April 1, 2026, and the board approved a 10% cut to the cash components of non-employee director pay. The company also announced a pilot trial of its lead antibiotic candidate, ibezapolstat, in patients with multiply-recurrent C. difficile infection, with trial start-up later in March and first-patient enrollment expected in the fourth quarter of 2026, subject to appropriate funding.
CEO David P. Luci and Executive Chairman Robert J. DeLuccia will each have a $495,000 annual base salary, and CFO Robert G. Shawah will have $360,000, effective April 1, 2026
Director cash compensation, including board, chair and committee retainers, will be reduced by 10% effective April 1, 2026
The open-label pilot trial will enroll up to 20 patients who have had at least two recurrences within the past 12 months; data will inform a planned Phase 3 trial
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Acurx Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →